Castlight Health Announces Fourth Quarter and Full Year 2015 Results
Total Revenue of $75.3 Million for the Year, Up 65% Year Over Year
SAN FRANCISCO, CA--(Marketwired - February 17, 2016) - Castlight Health, Inc. (NYSE: CSLT), a leading health benefits platform provider, today announced results for its fourth quarter and full year ended December 31, 2015.
/EINPresswire.com/ -- "In 2015, we grew our annual recurring revenue (ARR) 41% year-over-year to $110 million, added 9 Fortune 500 customers and achieved Net Dollar Retention (NDR) of 116% due to strong uptake of our newest products Elevate and Action. While we did not achieve our growth objectives for the business, we made significant progress on several key initiatives in 2015 that lay the foundation for future growth," said Giovanni Colella, M.D., co-founder and chief executive officer of Castlight Health. "In 2016, we will be focused on accelerating sales velocity with our now ramped sale force, leveraging our comprehensive health benefits platform to deliver value to customers, and driving to cash flow break-even. We believe these initiatives along with our company-wide focus on execution will position us well to achieve our long-term goals."
Fourth Quarter Results
- Total revenue for the fourth quarter of 2015 was $21.3 million, an increase of 47% from the fourth quarter of 2014. Subscription revenue was $19.9 million, an increase of 50% on a year-over-year basis.
- Gross margin for the fourth quarter of 2015 was 54.7%, compared to a gross margin of 54.3% in the fourth quarter of 2014. Non-GAAP gross margin for the fourth quarter of 2015 was 58.6% compared to a non-GAAP gross margin of 58.3% in the fourth quarter of 2014.
- Operating loss for the fourth quarter of 2015 was $19.1 million, compared to an operating loss of $19.7 million in the fourth quarter of 2014. Non-GAAP operating loss for the fourth quarter of 2015 was $14.9 million, compared to a non-GAAP operating loss of $15.3 million in the fourth quarter of 2014.
- Net loss per basic and diluted share was $0.20 in the fourth quarter of 2015, compared to a net loss per basic and diluted share of $0.22 in the fourth quarter of 2014. The non-GAAP net loss per basic and diluted share for the fourth quarter of 2015 was $0.16, compared to a net loss per basic and diluted share of $0.17 in the fourth quarter of 2014. For both GAAP and non-GAAP purposes, the weighted average basic and diluted share count for the fourth quarter of 2015 was 95.0 million compared to 90.5 million in the fourth quarter of 2014.
- Total cash, cash equivalents and marketable securities were $133.8 million at the end of the fourth quarter of 2015. Cash used in operations for the fourth quarter of 2015 was $12.0 million, compared to $11.5 million used in operations in the fourth quarter of 2014.
Full Year 2015 Results
- Total revenue for 2015 was $75.3 million, an increase of 65% from 2014. Subscription revenue was $70.4 million, an increase of 69% on a year-over-year basis.
- Gross margin for 2015 was 55.2%, compared to a gross margin of 39.1% in 2014. Non-GAAP gross margin for 2015 was 58.6% compared to a non-GAAP gross margin of 42.2% in 2014.
- Operating loss for 2015 was $80.2 million, compared to an operating loss of $86.2 million in 2014. Non-GAAP operating loss for 2015 was $64.5 million, compared to a non-GAAP operating loss of $69.6 million in 2014.
- Net loss per basic and diluted share was $0.85 in 2015, compared to a net loss per basic and diluted share of $1.16 in 2014. The non-GAAP net loss per basic and diluted share for 2015 was $0.68, compared to a net loss per basic and diluted share of $0.93 in 2014. For both GAAP and non-GAAP purposes, the weighted average basic and diluted share count for 2015 was 93.8 million compared to 74.4 million in 2014.
- Total cash, cash equivalents and marketable securities were $133.8 million at the end of 2015.
A reconciliation of GAAP to non-GAAP results has been provided in this press release in the accompanying tables. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures".
Business Outlook
Q1 2016 Guidance: Revenue for the company's first quarter is expected to be $22.0 million to $22.3 million. We expect to generate a non-GAAP operating loss in the range of $14.7 million to $15.7 million and a non-GAAP net loss per share of $0.15 to $0.16 based on 96 million weighted average basic and diluted shares outstanding.
Full Year 2016 Guidance: Revenue for the company's full year 2016 is expected to be in the range of $99.0 million to $102.0 million, an increase of 31% to 35% year-over-year. Non-GAAP operating loss is expected to be in the range of $47.0 million to $50.0 million. Non-GAAP basic and diluted loss per share is expected to be in the range of $0.47 to $0.51 based on 98 million to 99 million weighted average basic and diluted common shares outstanding.
For both the first quarter and the full year 2016, non-GAAP guidance excludes the effects of stock-based compensation expense and capitalization and amortization of internal-use software.
Quarterly Conference Call
Castlight Health will host a conference call to discuss its fourth quarter and full year 2015 results today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). A live audio webcast of the conference call, together with detailed financial information, can be accessed through the company's Investor Relations website at http://ir.castlighthealth.com. In addition, an archive of the webcast can be accessed through the same link. Participants who choose to call in to the conference call can do so by dialing 1-877-201-0168. The conference ID number is 24103644. A replay will be available for one week at 1-855-859-2056, passcode 24103644.
About Castlight Health
Our mission is to empower people to make the best choices for their health and to help companies make the most of their health benefits. We offer a health benefits platform that engages employees to make better healthcare decisions and guide them to the right program, care, and provider. The platform also enables benefit leaders to communicate and measure their programs while driving employee engagement with targeted, relevant communications. Castlight has partnered with more than 190 customers, spanning millions of lives, to improve healthcare outcomes, lower costs, and increase benefits satisfaction.
For more information visit www.castlighthealth.com. Follow us on Twitter and LinkedIn and Like us on Facebook.
Non-GAAP Financial Measures
To supplement Castlight Health's financial statements presented in accordance with generally accepted accounting principles (GAAP), we also use and provide investors and others with non-GAAP measures of certain components of financial performance, including non-GAAP gross margin, non-GAAP operating expense, non-GAAP operating loss, non-GAAP net loss and non-GAAP net loss per share. These non-GAAP financial measures differ from GAAP financial measures in that they exclude stock-based compensation, warrant expense, capitalization and amortization of internal-use software and the associated tax impact of these items, where applicable.
We believe that these non-GAAP financial measures provide useful supplemental information to investors and others, facilitate the analysis of the company's core operating results and comparison of operating results across reporting periods, and can help enhance overall understanding of the company's historical financial performance.
We have provided a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure, except that we have not reconciled our non-GAAP operating loss and net loss per share guidance for the first quarter and full year 2016 to comparable GAAP operating loss and net loss per share guidance because we do not provide guidance for stock-based compensation expense and capitalization and amortization of internal-use software, which are reconciling items between GAAP and non-GAAP operating loss. The factors that may impact our future stock-based compensation expense and capitalization and amortization of internal-use software are out of our control and/or cannot be reasonably predicted, and therefore we are unable to provide such guidance without unreasonable effort.
These non-GAAP financial measures should be considered in addition to, not as a substitute for or in isolation from, measures prepared in accordance with GAAP. Further, these non-GAAP measures may differ from the non-GAAP information used by other companies, including peer companies, and therefore comparability may be limited. Castlight Health encourages investors and others to review the company's financial information in its entirety and not rely on a single financial measure.
Safe Harbor For Forward-Looking Statements
This press release contains forward-looking statements about Castlight Health's expectations, plans, intentions, and strategies, including, but not limited to, statements regarding Castlight Health's first quarter and 2016 full year projections, our expectations for future performance of our business, market growth and business conditions, future innovation by the company and future developments with respect to the digital healthcare industry. Statements including words such as "anticipate," "believe," "estimate," "will," "continue," "expect," or "future," and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in Castlight Health's documents filed with or furnished to the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Castlight Health as of the date hereof. Castlight Health assumes no obligation to update these forward-looking statements.
Copyright 2016 Castlight Health, Inc. Castlight Health
CASTLIGHT HEALTH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
As of
---------------------------
December 31, December 31,
2015 2014
------------- -------------
(unaudited)
Assets
Current assets:
$
Cash and cash equivalents 19,150 $ 17,425
Marketable securities 101,274 175,057
Accounts receivable, net 12,751 11,097
Deferred commissions 5,438 3,675
Prepaid expenses and other current assets 3,772 3,476
------------- -------------
Total current assets 142,385 210,730
Property and equipment, net 6,896 3,630
Marketable securities, noncurrent 13,335 6,220
Restricted cash, noncurrent 1,000 -
Deferred commissions, noncurrent 4,923 2,563
Other assets 4,735 131
------------- -------------
Total assets $ 173,274 $ 223,274
============= =============
Liabilities and stockholders' equity
Current liabilities:
Accounts payable $ 3,384 $ 3,217
Accrued expenses and other current liabilities 4,550 5,791
Accrued compensation 11,477 10,455
Deferred revenue 26,590 20,708
------------- -------------
Total current liabilities 46,001 40,171
Deferred revenue, noncurrent 7,522 6,652
Other liabilities, noncurrent 1,397 261
------------- -------------
Total liabilities 54,920 47,084
Stockholders' equity 118,354 176,190
------------- -------------
Total liabilities and stockholders' equity $ 173,274 $ 223,274
============= =============
CASTLIGHT HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(unaudited)
Three Months Ended
December 31, Year Ended December 31,
----------------------------------------------------
2015 2014 2015 2014
------------- ------------ ------------ ------------
Revenue:
Subscription $ 19,933 $ 13,309 $ 70,350 $ 41,602
Professional services 1,382 1,178 4,965 4,003
------------- ------------ ------------ ------------
Total revenue 21,315 14,487 75,315 45,605
------------- ------------ ------------ ------------
Cost of revenue:
Cost of subscription
(1) 3,885 2,249 12,417 10,472
Cost of professional
services (1) 5,770 4,368 21,351 17,300
------------- ------------ ------------ ------------
Total cost of revenue 9,655 6,617 33,768 27,772
------------- ------------ ------------ ------------
Gross profit 11,660 7,870 41,547 17,833
------------- ------------ ------------ ------------
Operating expenses:
Sales and marketing (1) 16,579 15,798 67,414 62,065
Research and
development (1) 8,224 6,284 30,077 22,917
General and
administrative (1) 5,983 5,536 24,274 19,009
------------- ------------ ------------ ------------
Total operating expenses 30,786 27,618 121,765 103,991
------------- ------------ ------------ ------------
Operating loss (19,126) (19,748) (80,218) (86,158)
Other income, net 68 64 298 218
------------- ------------ ------------ ------------
Net loss $ (19,058) $ (19,684) $ (79,920) $ (85,940)
============= ============ ============ ============
Net loss per share,
basic and diluted $ (0.20) $ (0.22) $ (0.85) $ (1.16)
============= ============ ============ ============
Weighted-average shares
used to compute basic
and diluted net loss
per share 94,969 90,467 93,753 74,381
============= ============ ============ ============
_______________________
- Includes stock-based compensation expense as follows:
Three Months Ended
December 31, Year Ended December 31,
------------------------ ------------------------
2015 2014 2015 2014
------------ ----------- ----------- ------------
Cost of revenue:
Cost of subscription $ 87 $ 81 $ 283 $ 180
Cost of professional
services 653 494 2,175 1,220
Sales and marketing 1,822 1,594 7,705 5,933
Research and development 1,154 1,081 3,498 2,556
General and administrative 1,069 1,349 4,169 4,312
CASTLIGHT HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(unaudited)
Three Months Ended
December 31, Year Ended December 31,
-------------------------- -------------------------
2015 2014 2015 2014
------------- ------------ ------------ ------------
Operating activities:
Net loss $ (19,058) $ (19,684) $ (79,920) $ (85,940)
Adjustments to reconcile
net loss to net cash
used in operating
activities:
Depreciation 646 410 2,024 1,354
Stock-based
compensation 4,785 4,599 17,830 14,201
Amortization of
deferred commissions 934 973 3,510 4,092
Accretion and
amortization of
marketable securities 259 468 1,385 1,489
Expense related to
warrant - (20) - 2,639
Changes in operating
assets and
liabilities:
Accounts receivable 894 181 (1,654) (6,032)
Deferred commissions (4,287) (1,235) (7,633) (4,861)
Prepaid expenses and
other assets 1,354 27 328 (1,895)
Accounts payable (70) (46) 646 147
Accrued expenses and
other liabilities 1,604 1,529 (136) 4,282
Deferred revenue 982 1,254 6,752 15,887
------------- ------------ ------------ ------------
Net cash used in
operating activities (11,957) (11,544) (56,868) (54,637)
------------- ------------ ------------ ------------
Investing activities:
Restricted cash - - (1,000) 101
Investment in related
party - - (4,125) -
Purchase of property
and equipment (1,877) (462) (5,376) (1,860)
Purchase of marketable
securities (33,543) (19,928) (119,867) (230,316)
Sales of marketable
securities - - 5,000 13,000
Maturities of
marketable securities 40,092 22,762 180,111 76,527
------------- ------------ ------------ ------------
Net cash provided by
(used in) investing
activities 4,672 2,372 54,743 (142,548)
------------- ------------ ------------ ------------
Financing activities:
Proceeds from the
exercise of stock
options 764 1,366 3,944 3,294
Payments of deferred
financing costs - - (94) (3,781)
Proceeds from initial
public offering - - - 189,943
------------- ------------ ------------ ------------
Net cash provided by
financing activities 764 1,366 3,850 189,456
------------- ------------ ------------ ------------
Net (decrease) increase
in cash and cash
equivalents (6,521) (7,806) 1,725 (7,729)
Cash and cash
equivalents at
beginning of period 25,671 25,231 17,425 25,154
------------- ------------ ------------ ------------
Cash and cash
equivalents at end of
period $ 19,150 $ 17,425 $ 19,150 $ 17,425
============= ============ ============ ============
CASTLIGHT HEALTH, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(In thousands, except per share data)
(unaudited)
Year Ended
Three Months Ended
------------------------------ -------------------
December
31, September December
2015 30, 31, December December
2015 2014 31, 2015 31, 2014
---------- --------- --------- --------- ---------
Gross profit:
GAAP gross profit
subscription $16,048 $15,152 $11,060 $57,933 $31,130
GAAP gross margin
subscription 80.5 % 83.1 % 83.1 % 82.3 % 74.8 %
Stock-based
compensation expense 87 96 81 283 180
Amortization of
internal-use software 124 24 8 196 8
---------- --------- --------- --------- ---------
Non-GAAP gross profit
subscription $16,259 $15,272 $11,149 $58,412 $31,318
========== ========= ========= ========= =========
Non-GAAP gross margin
subscription 81.6 % 83.8 % 83.8 % 83 % 75.3 %
GAAP gross loss (16,38 (13,29
professional services $(4,388) $(4,300) $(3,190) $ 6) $ 7)
GAAP gross loss
percentage professional
services (318 )% (329 )% (271 )% (330 )% (332 )%
Stock-based
compensation expense 653 647 494 2,175 1,220
Capitalization of
internal-use software (30) (33) - (63) -
---------- --------- --------- --------- ---------
Non-GAAP gross loss (14,27 (12,07
professional services $(3,765) $(3,653) $(2,696) $ 4) $ 7)
========== ========= ========= ========= =========
Non-GAAP gross loss
percentage professional
services (272 )% (282 )% (229 )% (287 )% (302 )%
GAAP gross profit $11,660 $10,852 $ 7,870 $41,547 $17,833
GAAP gross margin 54.7 % 55.5 % 54.3 % 55.2 % 39.1 %
Impact of non-GAAP
adjustments 834 734 583 2,591 1,408
---------- --------- --------- --------- ---------
Non-GAAP gross profit $12,494 $11,586 $ 8,453 $44,138 $19,241
========== ========= ========= ========= =========
Non-GAAP gross margin 58.6 % 59.3 % 58.3 % 58.6 % 42.2 %
Operating expense:
GAAP sales and marketing $16,579 $16,731 $15,798 $67,414 $62,065
Expense related to
warrant - - 20 - (2,639)
Stock-based compensation
expense (1,822) (2,058) (1,594) (7,705) (5,933)
---------- --------- --------- --------- ---------
Non-GAAP sales and
marketing $14,757 $14,673 $14,224 $59,709 $53,493
========== ========= ========= ========= =========
GAAP research and
development $ 8,224 $ 7,868 $ 6,284 $30,077 $22,917
Stock-based compensation
expense (1,154) (981) (1,081) (3,498) (2,556)
Capitalization of
internal-use software 620 841 129 2,256 291
---------- --------- --------- --------- ---------
Non-GAAP research and
development $ 7,690 $ 7,728 $ 5,332 $28,835 $20,652
========== ========= ========= ========= =========
GAAP general and
administrative $ 5,983 $ 6,311 $ 5,536 $24,274 $19,009
Stock-based compensation
expense (1,069) (1,177) (1,349) (4,169) (4,312)
---------- --------- --------- --------- ---------
Non-GAAP general and
administrative $ 4,914 $ 5,134 $ 4,187 $20,105 $14,697
========== ========= ========= ========= =========
121,76 103,99
GAAP operating expense $30,786 $30,910 $27,618 $ 5 $ 1
Impact of non-GAAP (13,11 (15,14
adjustments (3,425) (3,375) (3,875) 6) 9)
---------- --------- --------- --------- ---------
Non-GAAP operating 108,64
expense $27,361 $27,535 $23,743 $ 9 $88,842
Operating loss:
(19,12 (20,05 (19,74 (80,21 (86,15
GAAP operating loss $ 6) $ 8) $ 8) $ 8) $ 8)
Impact of non-GAAP
adjustments 4,259 4,109 4,458 15,707 16,557
---------- --------- --------- --------- ---------
(14,86 (15,94 (15,29 (64,51 (69,60
Non-GAAP operating loss $ 7) $ 9) $ 0) $ 1) $ 1)
========== ========= ========= ========= =========
Net loss and net loss per
share:
(19,05 (20,00 (19,68 (79,92 (85,94
GAAP net loss $ 8) $ 7) $ 4) $ 0) $ 0)
Total pre-tax impact of
non-GAAP adjustments 4,259 4,109 4,458 15,707 16,557
Income tax impact of
non-GAAP adjustments - - - - -
---------- --------- --------- --------- ---------
(14,79 (15,89 (15,22 (64,21 (69,38
Non-GAAP net loss $ 9) $ 8) $ 6) $ 3) $ 3)
========== ========= ========= ========= =========
Basic and Diluted net
loss per share
GAAP $ (0.20) $ (0.21) $ (0.22) $ (0.85) $ (1.16)
========== ========= ========= ========= =========
Non-GAAP $ (0.16) $ (0.17) $ (0.17) $ (0.68) $ (0.93)
========== ========= ========= ========= =========
Shares used in basic and
diluted net loss per
share computation 94,969 94,409 90,467 93,753 74,381
========== ========= ========= ========= =========
Investor Contact:
Charles Butler
ir@castlighthealth.com
415-829-1400
Media Contact:
Jim Rivas
press@castlighthealth.com
415-829-1568
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
